Advertisement

Improved Prognosis in ALL with Modified BFM Protocols — Preliminary Results from Turkey

  • L. Sağlamer
  • L. Ulukutlu
  • İ. Yıldız
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 36)

Abstract

Intensive multiagent chemotherapy and central nervous system prophylaxis has resulted in remarkably improved event-free survival (EFS) approaching 80% in children with acute lymphoblastic leukemia (ALL) [1, 2, 3]. In contrast, prognosis of childhood ALL has remained poor with conventional treatment in our department with an overall long-term survival of 13% and an event-free interval (EFI) of 12%. Similar results have been reported from other centers in Turkey [4]. Besides the quality of chemotherapy; supportive care measures, access to drugs, patient incompliance and socioeconomic conditions are important factors in developing countries [4, 5], leading to reluctance in the institution of intensive regimens.

Keywords

Acute Lymphoblastic Leukemia Standard Risk Intensive Regimen Central Nervous System Prophylaxis Childhood Acute Lymphoblastic Leukaemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Steinherz PG, Gaynon P, Miller DR et al. (1986) Improved disease free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen - a new intensive therapy protocol: a report from the Children’s Cancer Study Group. J Clin Oncol 4: 744–752PubMedGoogle Scholar
  2. 2.
    Clavell LA, Gelber RD, Cohen HJ et al. (1986) Four-agent induction and intensive asparaginase therapy for treatment of childhood acute Iymphoblastic leukemia. New Engl J Med 315: 657–663PubMedCrossRefGoogle Scholar
  3. 3.
    Riehm H, Gadner H, Henze G et al. (1990) Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol Blood Transf 33: 439–450Google Scholar
  4. 4.
    Hiçsönmez G, Özsoylu S, Yetgin S et al. (1983) Poor prognosis of childhood acute lymphoblastic leukaemia [Letter]. Br Med J 286: 1437CrossRefGoogle Scholar
  5. 5.
    Ulukutlu L, Saǧlamer L, YlldlZ İ (1987) Results of chemotherapy in acute nonlymphoblastic leukemia in children. Farmaci Terapia 4: 291–294Google Scholar
  6. 6.
    Boilletot A, Behar C, Benoit Y et al. (1987) Treatment of acute lymphoblastic leukemia in children with the BFM protocol. Am J Pediatr Hematol Oncol 9: 317–323CrossRefGoogle Scholar
  7. 7.
    Aversa L, Garay G, Jimenez E et al. (1987) Treatment of children acute lymphoblastic leukemia (ALL) with a modified “BFM” pilot protocol [Abstract]. Proc ASCO: 156Google Scholar
  8. 8.
    Schrappe M, Beck J, Brandeis WE et al. (1987) Die Behandlung der akuten Iymphoblastischen Leukämie im Kindes- und Jugendalter: Ergebnisse der multizentrischen Therapiestudie ALL-BFM 81. Kin Pädiat 199: 133–150CrossRefGoogle Scholar
  9. 9.
    Bennett JM, Catovsky D, Daniel MT et al. (1976) Proposals for the classification of the acute leukemias. Br J Hematol 33: 451–458CrossRefGoogle Scholar
  10. 10.
    Langermann HJ, Henze G, Wulf M, Riehm H (1982) Abschätzung der Tumorzellmasse bei der akuten Iymphoblastischen Leukämie im Kindesalter: prognostische Bedeutung und praktische Anwendung. Klin Pädiat 194: 209–213CrossRefGoogle Scholar
  11. 11.
    Riehm H, Reiter A, Schrappe M et al. (1986) Die Corticosteroid-abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten Iymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83). Klin Pädiat 199: 151–160CrossRefGoogle Scholar
  12. 12.
    Henze G, Fengler R, Hartmann R et al. (1989) Chemotherapy for bone marrow relapse of childhood acute lymphoblastic leukemia. Cancer Chern Pharmacol 24 (Suppl 1): 16–19Google Scholar
  13. 13.
    Dawson-Saunders B, Trapp RG (1990) Methods for analyzing survival data. In: Basic and clinical biostatistics. Appleton & Lange, San Mateo Norwalk, pp 186–206Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • L. Sağlamer
    • 1
  • L. Ulukutlu
    • 1
  • İ. Yıldız
    • 1
  1. 1.Department of Pediatric Hematology-Oncology, Cerrahpaşa Medical SchoolUniversity of İstanbulTurkey

Personalised recommendations